Objectives: To assess the efficacy of tadalafil de-escalation in the therapeutic effects of psychogenic erectile dysfunction (ED) during the 3 months extension phase. Methods: A total of 90 men with mild to severe psychogenic ED were randomly divided into 2 groups: tadalafil 5 mg group and tadalafil de-escalation group. Efficacy assessments included the 5-item version of International Index of Erectile Function (IIEF-5), the Sexual Encounter Profile (SEP) questionnaires, Psychological and Interpersonal Relationship Scales (PAIRS), Erection Hardness Score (EHS). Results: Compared with the baseline, tadalafil 5 mg and de-escalation groups enhanced all efficacy outcomes. Patients receiving tadalafil 5 mg and de-escalation experienced a significant mean improvement in the psychogenic erectile function domain of the IIEF-5 from the baseline (p < 0.01). The mean change from baseline was significantly higher for the tadalafil de-escalation group than for the tadalafil 5 mg group (p < 0.05). Response to SEP3, PAIRS and EHS was significantly higher in the tadalafil de-escalation group than in the tadalafil 5 mg group (p < 0.05). The severity of ED in the tadalafil de-escalation group had reduced after treatment. It was also significantly better than those in the tadalafil 5 mg group (p < 0.05). Conclusion: Tadalafil de-escalation significantly improved the erectile function among psychogenic ED patients. This implies that tadalafil de-escalation treatment for psychogenic ED is worthy of further clinical practice and research.

Ayta IA, McKinlay JB, Krane RJ: The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int 1999;84:50-56.
Shamloul R, Ghanem H: Erectile dysfunction. Lancet 2013;381:153-165.
Lizza EF, Rosen RC: Definition and classification of erectile dysfunction: report of the nomenclature committee of the international society of impotence research. Int J Impot Res 1999;11:141-143.
Bai Q, Xu QQ, Jiang H, Zhang WL, Wang XH, Zhu JC: Prevalence and risk factors of erectile dysfunction in three cities of China: a community-based study. Asian J Androl 2004;6:343-348.
Yuxin T, Yu G, Leye H: Recent progression for application of tadalafil. Sci Res Essays 2011;6:6769-6773.
Egerdie RB, Auerbach S, Roehrborn CG, Costa P, Garza MS, Esler AL, Wong DG, Secrest RJ: Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study. J Sex Med 2012;9:271-281.
Coward RM, Carson CC: Tadalafil in the treatment of erectile dysfunction. Ther Clin Risk Manag 2008;4:1315-1330.
Shamloul R, Ghanem H: Erectile dysfunction. Lancet 2013;381:153-165.
McVary KT, Roehrborn CG, Kaminetsky JC, Auerbach SM, Wachs B, Young JM, Esler A, Sides GD, Denes BS: Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2007;177:1401-1407.
Roehrborn CG, McVary KT, Elion-Mboussa A, Viktrup L: Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. J Urol 2008;180:1228-1234.
Zhao C, Kim SW, Yang DY, Kim JJ, Park NC, Lee SW, Paick JS, Ahn TY, Min KS, Park K, Park JK: Efficacy and safety of once-daily dosing of udenafil in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial. Eur Urol 2011;60:380-387.
Rhoden EL, Telöken C, Sogari PR, Vargas Souto CA: The use of the simplified international index of erectile function (IIEF-5) as a diagnostic tool to study the prevalence of erectile dysfunction. Int J Impot Res 2002;14:245-250.
Sáenz de Tejada I, Anglin G, Knight JR, Emmick JT: Effects of tadalafil on erectile dysfunction in men with diabetes. Diabetes Care 2002;25:2159-2164.
Swindle RW, Cameron AE, Lockhart DC, Rosen RC: The psychological and interpersonal relationship scales: assessing psychological and relationship outcomes associated with erectile dysfunction and its treatment. Arch Sex Behav 2004;33:19-30.
Mulhall JP, Goldstein I, Bushmakin AG, Cappelleri JC, Hvidsten K: Validation of the erection hardness score. J Sex Med 2007;4:1626-1634.
Arduca P: Erectile dysfunction. A guide to diagnosis and management. Aust Fam Physician 2003;32:414-420.
Eardley I: The incidence, prevalence, and natural history of erectile dysfunction. Sex Med Rev 2013;1:3-16.
Li GY, Liang JH, Meng ZB, Huang CC, Liang SK, Wei GQ, Shen SL, Zhu CH, Zhang X, Song WR: [Low-dose testosterone undecanoate capsules combined with tadalafil for late-onset hypogonadism accompanied with ED]. Zhonghua Nan Ke Xue 2013;19:630-633.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.